Please ensure Javascript is enabled for purposes of website accessibility

Johnson & Johnson Hit With $750 Million Fine Over Baby Powder Legal Case

By Mark Prvulovic - Feb 6, 2020 at 8:56PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pharmaceutical giant lost another major legal battle today.

On Thursday afternoon, news broke that a New Jersey state jury had ordered Johnson & Johnson (JNJ -0.09%) to pay $750 million in punitive damages to four plaintiffs. The jury had concluded that the company's baby powder product had contained carcinogenic substances and the company hadn't properly informed consumers about the risk.

Johnson & Johnson faces over 16,800 lawsuits concerning its talc products, which are alleged to have contained carcinogenic substances that directly lead to ovarian cancer and rare cancers such as mesothelioma. Although the pharmaceutical giant has denied that any of its products contained carcinogens, a separate jury ordered Johnson & Johnson to pay $37.3 million in compensatory damages during the first phase of this same case back in 2019.

A gavel and hammer, law books, and a scale on a wooden table.

Image source: Getty Images.

While the jury ordered the company to pay $750 million to the four individuals, presiding judge Ana C. Viscomi stated that she would reduce the fine to just $186.5 million. Under state law, punitive damages can't be more than five times the amount of compensatory damages fined.

A growing number of legal defeats

Johnson's Baby Powder is one of the company's most recognizable products, with an extensive history that goes back to 1894. The trial also marked the first time in which Johnson & Johnson's CEO, Alex Gorsky, testified in the courtroom over the safety of the company's Baby Powder product.

In recent years, the company has been on the receiving end of a number of significant fines. Back in 2018, a separate lawsuit regarding the company's talc products resulted in Johnson & Johnson being forced to pay $4.7 billion to 22 women who claimed to have contracted ovarian cancer through those products.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$179.46 (-0.09%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
332%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.